Insider · CIK 0001873905

Tak Paul Peter

Reports to the SEC for 1 company · NEEDHAM, MA

sec.gov

Transactions

Companies

Filings

CIK

0001873905

Forms 4 and 5

Insider transactions

24 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-11	CADLCandel Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−59.4K sh	$10.46	−$621K	113,321
2026-09-10	CADLCandel Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+125K sh	$1.55	+$194K	393,566
2026-09-10	CADLCandel Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−221K sh	$11.50	−$2.54M	172,700
2026-09-10	CADLCandel Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−125K sh	—	—	1,638,968
2026-01-26	CADLCandel Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+629K sh	—	—	629,000
2025-06-25	CADLCandel Therapeutics, Inc.A Award	Director, Chief Executive Officer	AAward	+42.8K sh	$4.67	+$200K	268,566
2025-03-19	CADLCandel Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−400 sh	$9.00	−$3,601	225,740
2025-03-18	CADLCandel Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−25.8K sh	$8.77	−$226K	226,140
2025-02-12	CADLCandel Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+525K sh	—	—	525,000
2025-01-15	CADLCandel Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−21.7K sh	$7.22	−$157K	251,912
2025-01-08	CADLCandel Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−21.2K sh	$8.22	−$174K	273,616
2024-11-29	CADLCandel Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−48.8K sh	$4.56	−$223K	294,788
2024-11-21	CADLCandel Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+12.9K sh	$1.55	+$20K	343,635
2024-11-21	CADLCandel Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−12.9K sh	—	—	1,763,968
2024-07-17	CADLCandel Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−22.5K sh	$6.47	−$146K	330,735
2024-07-11	CADLCandel Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−20.3K sh	$5.97	−$121K	353,263
2023-11-28	CADLCandel Therapeutics, Inc.F Tax Payment	Director, Chief Executive Officer	FTax Payment	−43.4K sh	$0.90	−$39.1K	373,556
2023-11-26	CADLCandel Therapeutics, Inc.A Award	Director, Chief Executive Officer	AAward	+180K sh	—	—	416,999
2023-04-28	CADLCandel Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+180K sh	—	—	180,000
2022-12-09	CADLCandel Therapeutics, Inc.P Purchase	Director, Chief Executive Officer	PPurchase	+12.9K sh	$1.92	+$24.8K	40,985
2022-12-08	CADLCandel Therapeutics, Inc.P Purchase	Director, Chief Executive Officer	PPurchase	+3,050 sh	$1.70	+$5,185	28,050
2022-11-28	CADLCandel Therapeutics, Inc.A Award	Director, Chief Executive Officer	AAward	+196K sh	—	—	220,906
2022-02-28	CADLCandel Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+330K sh	—	—	330,000
2021-07-29	CADLCandel Therapeutics, Inc.P Purchase	Director, Chief Executive Officer	PPurchase	+25K sh	$8.00	+$200K	25,000

Recent filings

Accepted (ET)
Sep 114
Tak Paul Peter0001873905-26-000002
SEC(opens sec.gov)
Jan 284
Tak Paul Peter0001193125-26-027396
SEC(opens sec.gov)
Jun 264
Tak Paul Peter0000950170-25-090198
SEC(opens sec.gov)
Mar 204
Tak Paul Peter0000950170-25-042725
SEC(opens sec.gov)
Feb 144
Tak Paul Peter0000950170-25-021283
SEC(opens sec.gov)
Jan 174
Tak Paul Peter0000950170-25-006724
SEC(opens sec.gov)
Jan 104
Tak Paul Peter0000950170-25-004198
SEC(opens sec.gov)
Dec 34
Tak Paul Peter0000950170-24-132930
SEC(opens sec.gov)
Nov 214
Tak Paul Peter0000950170-24-129677
SEC(opens sec.gov)
Jul 194
Tak Paul Peter0000950170-24-084761
SEC(opens sec.gov)
Jul 154
Tak Paul Peter0000950170-24-083401
SEC(opens sec.gov)
Nov 304
Tak Paul Peter0001209191-23-056987
SEC(opens sec.gov)
Nov 284
Tak Paul Peter0001209191-23-056801
SEC(opens sec.gov)
May 24
Tak Paul Peter0001209191-23-026581
SEC(opens sec.gov)
Dec 124
Tak Paul Peter0001209191-22-060689
SEC(opens sec.gov)

Companies

Candel Therapeutics, Inc.Director, Chief Executive OfficerCADL

Address

C/O CANDEL THERAPEUTICS, INC. 117 KENDRICK ST., SUITE 450

NEEDHAM, MA, 02494